3/31/2015 8:29 AM IPN.PA 44.72 € (+1.78 %) Data: Yahoo Finance
Startsidan

Press Releases

  • 3/4/2015

    Precisions concerning the resupply of Increlex® in the U.S.

    Precisions concerning the resupply of Increlex® in the U.S.
  • 3/3/2015

    Ipsen’s 2014 results and 2015 financial objectives

    Ipsen’s 2014 results and 2015 financial objectives
  • 3/2/2015

    Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015

    Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015
  • 3/2/2015

    Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer

    Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer
  • 2/24/2015

    Ipsen enters into option agreement to acquire Canbex Therapeutics

    Ipsen enters into option agreement to acquire Canbex Therapeutics
  • 2/3/2015

    Ipsen: sales in the fourth quarter and full year 2014

    Ipsen: sales in the fourth quarter and full year 2014
  • 1/26/2015

    Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults

    Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults
  • 1/7/2015

    Ipsen announces its corporate agenda for 2015

    Ipsen announces its corporate agenda for 2015
  • 12/17/2014

    Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors

    Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
  • 12/16/2014

    François Garnier appointed Executive Vice President, General Counsel of Ipsen

    François Garnier appointed Executive Vice President, General Counsel of Ipsen